Irritable Bowel Syndrome Market by Type, Drug Type, and Geography - Forecast and Analysis 2021-2025

  • Published: Jan 2022
  • Pages: 120
  • SKU: IRTNTR72042
Technavio

Purchase this report now and if we publish a new version within 90 days, we will send you a free copy.

Safe and Secure SSL Encrypted
  • 2500.00
  • USD

The irritable bowel syndrome market share is expected to increase by USD 779.89 million from 2020 to 2025, and the market’s growth momentum will accelerate at a CAGR of 10.09%.

This irritable bowel syndrome market research report provides valuable insights on the post COVID-19 impact on the market, which will help companies evaluate their business approaches. Furthermore, this report extensively covers irritable bowel syndrome market segmentation by type (IBS-D, IBS-C, and IBS-M), drug type (antibiotics, guanylate cyclase-C agonists, mu-opioid receptor agonists, chloride channel activators, and others), and geography (North America, Europe, Asia, and ROW). The irritable bowel syndrome market report also offers information on several market vendors, including AbbVie Inc., Alfasigma Spa, Astellas Pharma Inc., AstraZeneca Plc, Bausch Health Companies Inc., Ironwood Pharmaceuticals Inc., Mallinckrodt Plc, Novartis AG, Sebela Pharmaceuticals Inc., and Teva Pharmaceutical Industries Ltd. among others.

What will the Irritable Bowel Syndrome Market Size be During the Forecast Period?

Download the Free Report Sample to Unlock the Irritable Bowel Syndrome Market Size for the Forecast Period and Other Important Statistics

 

Irritable Bowel Syndrome Market: Key Drivers and Trends

The unhealthy lifestyle habits are notably driving the irritable bowel syndrome market growth, although factors such as counterfeit drugs may impede the market growth. Our research analysts have studied the historical data and deduced the key market drivers and the COVID-19 pandemic impact on the irritable bowel syndrome industry. The holistic analysis of the drivers will help in deducing end goals and refining marketing strategies to gain a competitive edge.

Key Irritable Bowel Syndrome Market Driver

One of the key factors driving the global irritable bowel syndrome market growth is the unhealthy lifestyle habits of people. The fast-paced world has compelled people to opt for takeaway food or fast food, which has high-fat content that is one of the primary causes of acidity that increases the risk of developing irritable bowel syndrome. According to the Centers for Disease Control and Prevention (CDC), during 2015-2019, 44.7% of adults in the US consumed fast food on any given day. Other factors causing the condition are the consumption of alcohol or tobacco in cigarettes/cigars. According to the CDC’s January 2021 report, excessive alcohol use causes approximately 95,000 deaths in the US each year. These incidences are increasing the need for the treatment for irritable bowel syndrome, which will positively impact the market in focus during the forecast period.

Key Irritable Bowel Syndrome Market Challenge

The high availability of counterfeit drugs is one of the key challenges to the global irritable bowel syndrome market growth. According to the US FDA, many illegal websites are selling unapproved drugs. These sellers go unnoticed owing to the inadequate regulations, especially in developing countries such as India, which will negatively impact the health of consumers and the growth of the market. For instance, according to a news article in the Times of India newspaper published in March 2018, 90,000 capsules and tablets of antacids and multivitamins were seized in Delhi by the crime branch. Therefore, the availability of counterfeit products and inadequate regulations will make the market penetration difficult for key vendors, which will hamper the global irritable bowel syndrome market growth.

This irritable bowel syndrome market analysis report also provides detailed information on other upcoming trends and challenges that will have a far-reaching effect on the market growth. The actionable insights on the trends and challenges will help companies evaluate and develop growth strategies for 2021-2025.

Who are the Major Irritable Bowel Syndrome Market Vendors?

The report analyzes the market’s competitive landscape and offers information on several market vendors, including:

 

  • AbbVie Inc.
  • Alfasigma Spa
  • Astellas Pharma Inc.
  • AstraZeneca Plc
  • Bausch Health Companies Inc.
  • Ironwood Pharmaceuticals Inc.
  • Mallinckrodt Plc
  • Novartis AG
  • Sebela Pharmaceuticals Inc.
  • Teva Pharmaceutical Industries Ltd.

 

This statistical study of the irritable bowel syndrome market encompasses successful business strategies deployed by the key vendors. The irritable bowel syndrome market is fragmented and the vendors are deploying growth strategies such as the introduction of effective new products to compete in the market.

To make the most of the opportunities and recover from post COVID-19 impact, market vendors should focus more on the growth prospects in the fast-growing segments, while maintaining their positions in the slow-growing segments.

The irritable bowel syndrome market forecast report offers in-depth insights into key vendor profiles. The profiles include information on the production, sustainability, and prospects of the leading companies. 

Which are the Key Regions for Irritable Bowel Syndrome Market?

For more insights on the market share of various regions Request for a FREE sample now!

40% of the market’s growth will originate from North America during the forecast period. The US is the key market for irritable bowel syndrome market in North America. Market growth in this region will be faster than the growth of the market in Europe and ROW.

The rapid increase in the number of patients with gastrointestinal diseases and disorders owing to an alteration in bowel habits, abdominal pain, a surge in the level of stress, and eating an unhealthy diet will facilitate the irritable bowel syndrome market growth in North America over the forecast period. This market research report entails detailed information on the competitive intelligence, marketing gaps, and regional opportunities in store for vendors, which will assist in creating efficient business plans.

What are the Revenue-generating Type Segments in the Irritable Bowel Syndrome Market?

To gain further insights on the market contribution of various segments Request for a FREE sample

The irritable bowel syndrome market share growth by the IBS-D segment will be significant during the forecast period. By 2025, irritable bowel syndrome market share by the IBS-D will be 49.90% of the total market. The significant increase in the demand for US Food and Drug Administration (FDA) approved drugs such as Xifaxan (rifaximin) and eluxadoline for the treatment of Irritable bowel syndrome will facilitate the growth of the market during the forecast period.

This report provides an accurate prediction of the contribution of all the segments to the growth of the irritable bowel syndrome market size and actionable market insights on post COVID-19 impact on each segment.

 

Irritable Bowel Syndrome Market Scope

Report Coverage

Details

Page number

120

Base year

2020

Forecast period

2021-2025

Growth momentum & CAGR

Accelerate at a CAGR of 10.09%

Market growth 2021-2025

$ 779.89 million

Market structure

Fragmented

YoY growth (%)

9.60

Regional analysis

North America, Europe, Asia, and ROW

Performing market contribution

North America at 40%

Key consumer countries

US, Germany, UK, China, and Japan

Competitive landscape

Leading companies, Competitive strategies, Consumer engagement scope

Key companies profiled

AbbVie Inc., Alfasigma Spa, Astellas Pharma Inc., AstraZeneca Plc, Bausch Health Companies Inc., Ironwood Pharmaceuticals Inc., Mallinckrodt Plc, Novartis AG, Sebela Pharmaceuticals Inc., and Teva Pharmaceutical Industries Ltd.

Market dynamics

Parent market analysis, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID-19 impact and recovery analysis and future consumer dynamics, Market condition analysis for the forecast period

Customization purview

If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized.

Request for a FREE sample

What are the Key Data Covered in this Irritable Bowel Syndrome Market Report?

  • CAGR of the market during the forecast period 2021-2025
  • Detailed information on factors that will drive irritable bowel syndrome market growth during the next five years
  • Precise estimation of the irritable bowel syndrome market size and its contribution to the parent market
  • Accurate predictions on upcoming trends and changes in consumer behavior
  • The growth of the irritable bowel syndrome industry across North America, Europe, Asia, and ROW
  • A thorough analysis of the market’s competitive landscape and detailed information on vendors
  • Comprehensive details of factors that will challenge the growth of irritable bowel syndrome market vendors

We can help! Our analysts can customize this report to meet your requirements. Get in touch

Read More Read Less

Executive Summary

    Market Landscape

    • Market ecosystem
    • Value chain analysis

    Market Sizing

    • Market definition
    • Market segment analysis
    • Market size 2020
    • Market outlook: Forecast for 2020 - 2025

    Five Forces Analysis

    • Bargaining power of buyers
    • Bargaining power of suppliers
    • Threat of new entrants
    • Threat of substitutes
    • Threat of rivalry
    • Market condition

    Market Segmentation by Type

    • Market segments
    • Comparison by Type
    • IBS-D - Market size and forecast 2020-2025
    • IBS-C - Market size and forecast 2020-2025
    • IBS-M - Market size and forecast 2020-2025
    • Market opportunity by Type

    Market Segmentation by Drug type

    • Market segments
    • Comparison by Drug type
    • Antibiotics - Market size and forecast 2020-2025
    • Guanylate cyclase-C agonists - Market size and forecast 2020-2025
    • Mu-opioid receptor agonists - Market size and forecast 2020-2025
    • Chloride channel activators - Market size and forecast 2020-2025
    • Others - Market size and forecast 2020-2025
    • Market opportunity by Drug type

    Customer landscape

      Geographic Landscape

      • Geographic segmentation
      • Geographic comparison
      • North America - Market size and forecast 2020-2025
      • Europe - Market size and forecast 2020-2025
      • Asia - Market size and forecast 2020-2025
      • ROW - Market size and forecast 2020-2025
      • Key leading countries
      • Market opportunity by geography
      • Market drivers
      • Market challenges
      • Market trends

      Vendor Landscape

      • Overview
      • Landscape disruption

      Vendor Analysis

      • Vendors covered
      • Market positioning of vendors
      • AbbVie Inc.
      • Alfasigma Spa
      • Astellas Pharma Inc.
      • AstraZeneca Plc
      • Bausch Health Companies Inc.
      • Ironwood Pharmaceuticals Inc.
      • Mallinckrodt Plc
      • Novartis AG
      • Sebela Pharmaceuticals Inc.
      • Teva Pharmaceutical Industries Ltd.

      Appendix

      • Scope of the report
      • Currency conversion rates for US$
      • Research methodology
      • List of abbreviations

      Research Framework

      Technavio presents a detailed picture of the market by way of study, synthesis, and summation of data from multiple sources. The analysts have presented the various facets of the market with a particular focus on identifying the key industry influencers. The data thus presented is comprehensive, reliable, and the result of extensive research, both primary and secondary.

      TechnavioINFORMATION SOURCES

      Primary sources

      • Manufacturers and suppliers
      • Channel partners
      • Industry experts
      • Strategic decision makers

      Secondary sources

      • Industry journals and periodicals
      • Government data
      • Financial reports of key industry players
      • Historical data
      • Press releases
      Technavio

      TechnavioDATA ANALYSIS

      Data Synthesis

      • Collation of data
      • Estimation of key figures
      • Analysis of derived insights

      Data Validation

      • Triangulation with data models
      • Reference against proprietary databases
      • Corroboration with industry experts
      Technavio

      TechnavioREPORT WRITING

      Qualitative

      • Market drivers
      • Market challenges
      • Market trends
      • Five forces analysis

      Quantitative

      • Market size and forecast
      • Market segmentation
      • Geographical insights
      • Competitive landscape
      Interested in this report?
      Get your FREE sample now!
      The irritable bowel syndrome market growth will increase by $779.89 million during 2020-2025.
      The irritable bowel syndrome market is expected to grow at a CAGR of 10.09% during 2020-2025.
      Technavio has segmented the irritable bowel syndrome market by type (IBS-D, IBS-C, and IBS-M) ,other1 (Antibiotics, Guanylate cyclase-C agonists, Mu-opioid receptor agonists, Chloride channel activators, and Others) , and geographic (North America, Europe, Asia, and ROW).
      AbbVie Inc., Alfasigma Spa, Astellas Pharma Inc., AstraZeneca Plc, Bausch Health Companies Inc., Ironwood Pharmaceuticals Inc., Mallinckrodt Plc, Novartis AG, Sebela Pharmaceuticals Inc., Teva Pharmaceutical Industries Ltd. are a few of the key vendors in the irritable bowel syndrome market.
      North America will register the highest growth rate of 39.89% among the other regions. Therefore, the irritable bowel syndrome market in North America is expected to garner significant business opportunities for the vendors during the forecast period.
      The key factors driving the irritable bowel syndrome market growth are:
      • Unhealthy lifestyle habits
      The irritable bowel syndrome market vendors should focus on grabbing business opportunities from the ibs-d segment as it accounted for the largest market share in the base year.
      Safe and Secure SSL Encrypted
      Technavio

      Single User:

      2500 USD

      Technavio Get the report (PDF) sent to your email within minutes.

      Subscribe & Save

      Get lifetime access to our
      Technavio Insights

      Want to customize this report?

      This report can be personalized according to your needs. Our analysts and industry experts will work directly with you to understand your requirements and provide you with customized data in a short amount of time.

      We offer $1000 worth of FREE customization at the time of purchase
      Technavio
      Enquire Before Buying
      1. Home
      2. Health Care
      3. Published Report
      17,000 reports available | Plans starting from just 5,000 USD | Get FREE trial>>